Inhibrx is a clinical-stage oncology biotech built around two active candidates: INBRX-106, its hexavalent OX40 agonist being tested in HNSCC and other immunogenic tumors, and ozekibart, its DR5 agonist being tested in sarcomas and colorectal cancer. This filing is an updated investor presentation rather than a new trial readout, but it materially sharpens the development plan for INBRX-106.
The business story advances from promising signal to a defined regulatory test. The company is adding 50 HPV-positive oropharyngeal cancer patients to the Phase 2 portion of HexAgon and lowering eligibility from PD-L1 CPS≥20 to CPS≥1, creating a broader prospective test of whether the benefit is driven by HPV biology rather than unusually high PD-L1 expression. The presentation says the expansion “may serve as potential path to accelerated approval by end of ‘28/early ‘29.” 〔0〕
| Metric | INBRX-106 + pembrolizumab | Pembrolizumab alone | Filing location |
|---|---|---|---|
| Overall cORR | 48.3% | 26.5% | Primary endpoint, HexAgon |
| HPV+ cORR | 80.0% | 33.3% | HPV+ subgroup |
| HPV+ PFS at 6 months | 90% | 33% | HPV+ durability |
| Median PFS, all patients | 9.6 months | 4.9 months | Overall durability |
| Grade ≥3 related adverse events | 48.4% | 11.8% | Safety and tolerability |
| Treatment discontinuation | 35.5% | 14.7% | Safety and tolerability |
The efficacy signal is genuinely large, but the evidence base is still small. The headline HPV-positive result is 8 responses out of 10 evaluable combination patients versus 3 of 9 on pembrolizumab, with a very wide 95% confidence interval for the difference of –2.7 to 80.3 percentage points. 〔1〕 That makes the expansion strategically sensible: it is designed to test whether the striking subgroup result survives a larger, less narrowly selected population rather than treating the first readout as definitive.
The cost of the stronger activity is a meaningful tolerability burden. In the combination arm, 48.4% of patients had grade 3 or higher treatment-related adverse events and 35.5% discontinued treatment, versus 11.8% and 14.7% respectively for pembrolizumab alone. 〔2〕 The company emphasizes that many common events were low grade, but the discontinuation and severe-event rates are the less promotional part of the presentation and remain important for the eventual benefit-risk case.
The rest of the presentation mostly repackages an already developing story. Ozekibart’s chondrosarcoma data, colorectal activity, cash position, and broader vaccine-combination thesis are presented as support for the platform, but this filing does not add a new registrational result, FDA agreement, approval, or financing. The central new information is the 50-patient HPV-positive expansion and the move to CPS≥1.
Bottom line: This is a modestly important clinical-development upgrade, not a clinical validation event. It gives INBRX-106 a clearer route to test and potentially accelerate the HPV-positive HNSCC program, while the small original subgroup and substantial combination toxicity mean the larger expansion still has to prove the story.
Read the original 8-K on SEC EDGAR ↗